Literature DB >> 30231413

The Role of Statistics in Regulatory Decision Making.

Lisa M LaVange1.   

Abstract

The number of statistical challenges facing regulators remains high, as does the importance of statistical thinking in the regulatory decision-making process. Statisticians in the Office of Biostatistics at the US Food and Drug Administration review hundreds of new drug and therapeutic biologic applications each year and advise sponsors on protocols numbering in the thousands. In addition to remaining up to date on the newest statistical methods, statisticians are often called upon for innovative approaches to difficult regulatory problems. This article presents the author's view of the important role that statisticians play in regulatory decision making, beginning with a broad overview of current office initiatives, including the development of guidance documents and a recent push for open and transparent collaboration with industry on methods development. Several recent examples are provided to illustrate the impact that statisticians can have on regulatory decisions through the use of strategic quantitative thinking. Also discussed are areas where it is believed that innovative statistical solutions or greater clarity on existing approaches is still needed.

Keywords:  adaptive design; data quality; meta-analysis; missing data; regulatory guidance; sensitivity analysis; statistical reviews

Year:  2014        PMID: 30231413     DOI: 10.1177/2168479013514418

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  4 in total

1.  Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.

Authors:  Marian Mitroiu; Steven Teerenstra; Katrien Oude Rengerink; Frank Pétavy; Kit C B Roes
Journal:  Pharm Stat       Date:  2022-06-09       Impact factor: 1.234

2.  Discussion on "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes" by David Benkeser, Ivan Diaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein, and Michael Rosenblum.

Authors:  Lisa M LaVange
Journal:  Biometrics       Date:  2021-06-09       Impact factor: 1.701

3.  4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

Authors:  Désirée van der Heijde; Atul Deodhar; Oliver FitzGerald; Roy Fleischmann; Dafna Gladman; Alice B Gottlieb; Bengt Hoepken; Lars Bauer; Oscar Irvin-Sellers; Majed Khraishi; Luke Peterson; Anthony Turkiewicz; Jürgen Wollenhaupt; Philip J Mease
Journal:  RMD Open       Date:  2018-03-14

4.  The Role of Expert Judgment in Statistical Inference and Evidence-Based Decision-Making.

Authors:  Naomi C Brownstein; Thomas A Louis; Anthony O'Hagan; Jane Pendergast
Journal:  Am Stat       Date:  2019-03-20       Impact factor: 8.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.